Moreover, preclinical studies demonstrate that gilteritinib exhibits inhibitory activity against c-Kit, AKT, and sodium-coupled neutral amino acid transporter 1 (SNAT1) pathways in AML cells (Mori et al., 2017; Zavorka Thomas et al., 2021). This evidence concerns the gene SLC38A1 and acute myeloid leukemia.